What Is 2C-BE

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2C-BE is a lesser-known psychedelic compound from the 2C family, first synthesized in 1974 by Alexander Shulgin. It is a structural analog of 2C-B and acts as a partial agonist at serotonin receptors, particularly 5-HT2A. Limited research exists, but anecdotal reports suggest effects last 4–6 hours with moderate potency.

Key Facts

2C-BE was first synthesized in 1974 by chemist Alexander Shulgin
It is a psychedelic phenethylamine and structural analog of 2C-B
Effects typically last 4 to 6 hours based on anecdotal user reports
It acts primarily on the 5-HT2A serotonin receptor as a partial agonist
2C-BE is not approved for medical use and remains a research chemical

Overview

2C-BE is a synthetic psychedelic substance belonging to the 2C family of phenethylamines. First documented by Alexander Shulgin in the 1970s, it is structurally related to other well-known psychedelics like 2C-B and 2C-I. Despite its classification, 2C-BE remains largely unexplored in clinical or academic settings.

Unlike regulated pharmaceuticals, 2C-BE has not undergone human trials for safety or therapeutic potential. It is primarily encountered in research chemical markets and underground psychedelic communities. Due to its obscurity, much of the available data comes from anecdotal reports rather than peer-reviewed studies.

Chemical class: 2C-BE is a phenethylamine derivative, part of a broader group known for hallucinogenic and stimulant properties.
Discovery date: Alexander Shulgin first synthesized 2C-BE in 1974 during his exploration of substituted phenethylamines.
Structural relation: It is a close analog of 2C-B, differing only in the substitution pattern on the benzene ring.
Legal status: Not approved for human use; classified as a research chemical with no medical applications in most countries.
Availability: Rarely found in mainstream markets, typically distributed through niche online vendors or underground labs.

How It Works

2C-BE interacts primarily with the brain's serotonin system, influencing perception, mood, and cognition. Its mechanism is similar to other psychedelics in the 2C family, though less potent than compounds like DOI or 2C-T-7.

5-HT2A Receptor: 2C-BE acts as a partial agonist at serotonin 5-HT2A receptors, which are key to its hallucinogenic effects and altered states of consciousness.
Dopamine Interaction: While primarily serotonergic, it may weakly influence dopamine pathways, contributing to mild stimulant-like effects in some users.
Metabolism: The compound is metabolized in the liver via CYP450 enzymes, though specific metabolic pathways remain poorly studied.
Onset and Duration: Effects typically begin within 30–60 minutes and last between 4 to 6 hours, depending on dosage and individual metabolism.
Dosage Range: Active doses range from 15 to 30 mg orally, with higher doses increasing risk of adverse reactions like anxiety or nausea.
Neuroplasticity: Like other psychedelics, it may promote short-term neuroplastic changes, though no studies confirm this for 2C-BE specifically.

Comparison at a Glance

Below is a comparison of 2C-BE with related compounds in the 2C family based on potency, duration, and receptor activity.

Compound	Potency (mg)	Duration	Primary Receptor	Legal Status
2C-BE	15–30 mg	4–6 hours	5-HT2A	Unregulated (research chemical)
2C-B	15–25 mg	4–8 hours	5-HT2A	Controlled (Schedule I in US)
2C-I	10–25 mg	6–10 hours	5-HT2A	Controlled (US)
2C-E	5–15 mg	6–8 hours	5-HT2A	Controlled (Schedule I)
2C-T-7	5–10 mg	8–12 hours	5-HT2A	Controlled (Schedule I)

While 2C-BE is less potent than 2C-E or 2C-T-7, it shares similar psychedelic properties. Its shorter duration and milder effects make it less popular than other 2C compounds. However, the lack of formal research limits definitive conclusions about its pharmacology and safety profile.

Why It Matters

Understanding 2C-BE is important for harm reduction, forensic science, and the study of psychedelic pharmacology. As new research chemicals emerge, identifying their effects and risks helps inform public health policies and clinical responses.

Harm Reduction: Accurate data on dosage and duration helps users avoid overdose or adverse reactions in unregulated settings.
Forensic Relevance: Law enforcement and toxicologists must recognize emerging analogs to detect and regulate new substances.
Neuroscience Research: Studying 2C-BE contributes to understanding serotonin receptor dynamics and psychedelic mechanisms.
Legal Loopholes: Its status as a research chemical highlights gaps in drug legislation that allow unregulated distribution.
Therapeutic Potential: Though unexplored, analogs like 2C-B show promise; 2C-BE could inform future psychedelic-assisted therapies.
User Safety: Clear information reduces reliance on anecdotal or misleading sources, promoting informed decision-making.

While 2C-BE remains obscure, its existence underscores the evolving landscape of designer psychedelics. As interest in altered states and mental health treatments grows, compounds like 2C-BE may attract more scientific scrutiny in the future.